Market capitalization | $53.68m |
Enterprise Value | $-4.49m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.06 |
EV/Sales (TTM) EV/Sales | -1.68 |
P/S ratio (TTM) P/S ratio | 20.10 |
P/B ratio (TTM) P/B ratio | 0.43 |
Revenue growth (TTM) Revenue growth | 2.74% |
Revenue (TTM) Revenue | $2.67m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
3 Analysts have issued a Singular Genomics Systems Inc forecast:
3 Analysts have issued a Singular Genomics Systems Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 2.67 2.67 |
3%
3%
|
|
Gross Profit | -8.20 -8.20 |
11%
11%
|
|
EBITDA | -86 -86 |
5%
5%
|
EBIT (Operating Income) EBIT | -93 -93 |
5%
5%
|
Net Profit | -86 -86 |
7%
7%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Singular Genomics Systems, Inc. engages in the development and commercialization of proprietary sequencing solutions. It develops two integrated solutions: G4 Instrument and PX Instrument. The G4 Instrument operates as a benchtop next generation sequencer designed to produce fast and accurate genetic sequencing results. The PX Instrument combines single cell and spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company was founded by Eli Glezer and Andrew Spaventa in June 2016 and is headquartered in La Jolla, CA.
Head office | United States |
CEO | Andrew Spaventa |
Employees | 265 |
Founded | 2016 |
Website | www.singulargenomics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.